Premium
Treatment of Infantile Hemangiomas with Sirolimus in a Patient with PHACE Syndrome
Author(s) -
Kaylani Samer,
Theos Amy J.,
Pressey Joseph G.
Publication year - 2013
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12023
Subject(s) - sirolimus , medicine , pathogenesis , infantile hemangioma , dermatology , hemangioma , surgery
Abstract Infantile hemangiomas ( IHs ) are common benign tumors of childhood. IH s often regress satisfactorily without intervention, but a subset of IH s may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas. We present an infant with PHACE syndrome and segmental IH that failed conventional first‐line therapies. Treatment with sirolimus provided benefit with regression of the cutaneous IH . As an inhibitor of the mammalian target of rapamycin (m TOR ) pathway, the effective use of sirolimus may shed light on the emerging role of m TOR signaling in the development and pathogenesis of IH s.